Jazz Pharmaceuticals plc (NASDAQ: JAZZ) signs an exclusive global license agreement with Saniona for development and commercialization of SAN2355. Saniona to receive $42.5 million upfront, eligible for up to $192.5 million in milestones. Jazz obtains exclusive rights to develop and commercialize SAN2355 for epilepsy and other indications, stock price up by over 4.5%.

SAN2355 is a selective small molecule that activates potassium channels to control nerve cell excitability, a potential best-in-class epilepsy treatment. Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, especially with limited treatment options. Stock price has risen positively since the announcement.

While Jazz Pharmaceuticals (JAZZ) shows promise as an investment, some AI stocks may offer greater upside potential and less downside risk. For an undervalued AI stock with benefits from Trump-era tariffs and onshoring trend, check out our free report on the best short-term AI stock. Discover 30 stocks that could double in 3 years and 11 hidden AI stocks to buy right now.

Read more at Yahoo Finance: Jazz Pharmaceuticals (JAZZ) Sings License with Saniona for SAN2355